CD8A and cancer: Given that CD8+ T cells with high PD-1 expression lose the ability to eliminate cancer due to the checkpoint inhibition, the higher level of signatures of PD-1-low effector CD8+ T cells in patients with positive outcome to chemotherapy is once again suggestive of a downstream adaptive immune response in these patients post chemotherapy administration.